These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 14696814)

  • 1. Treatment of visceral leishmaniasis.
    Ozsoylu S
    Turk J Pediatr; 2003; 45(3):280. PubMed ID: 14696814
    [No Abstract]   [Full Text] [Related]  

  • 2. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
    Dilber E; Erduran E; Işik Y
    Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune mediated hemolysis in visceral leishmaniasis.
    Mahajan V; Marwaha RK
    J Trop Pediatr; 2007 Aug; 53(4):284-6. PubMed ID: 17483492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kala-azar associated with coombs-positive autoimmune hemolytic anemia in the patients coming from the endemic area of this disease and successful treatment of these patients with liposomal amphotericin B.
    Erduran E; Bahadir A; Gedik Y
    Pediatr Hematol Oncol; 2005; 22(5):349-55. PubMed ID: 16020124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of visceral leishmaniasis with liposomal amphotericin B.
    Lagler H; Matt U; Sillaber C; Winkler S; Graninger W
    Acta Biomed; 2006; 77 Suppl 2():22-5. PubMed ID: 16918063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Berman JD
    Clin Infect Dis; 1999 Jan; 28(1):49-51. PubMed ID: 10391695
    [No Abstract]   [Full Text] [Related]  

  • 7. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
    Manfredi R; Marinacci G; Calza L; Passarini B
    Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
    [No Abstract]   [Full Text] [Related]  

  • 8. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome).
    Boletis JN; Pefanis A; Stathakis C; Helioti H; Kostakis A; Giamarellou H
    Clin Infect Dis; 1999 Jun; 28(6):1308-9. PubMed ID: 10451172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Meyerhoff A
    Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B.
    Mishra M
    J Assoc Physicians India; 1995 Apr; 43(4):306. PubMed ID: 8713286
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
    Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune haemolytic anaemia due to visceral leishmaniasis in a young child.
    Boel M
    Eur J Pediatr; 2003 Jun; 162(6):444; author reply 445. PubMed ID: 12712333
    [No Abstract]   [Full Text] [Related]  

  • 13. ABLE: a new and improved amphotericin B for visceral leishmaniasis?
    Berman J
    Am J Trop Med Hyg; 2009 May; 80(5):689-90. PubMed ID: 19407106
    [No Abstract]   [Full Text] [Related]  

  • 14. Visceral leishmaniasis in a patient with Wegener's granulomatosis.
    Sollima S; Corbellino M; Piolini R; Calattini S; Imparato S; Antinori S
    Rheumatology (Oxford); 2004 Jul; 43(7):935-7. PubMed ID: 15213342
    [No Abstract]   [Full Text] [Related]  

  • 15. Amphotericin B in visceral leishmaniasis.
    Jha BB
    Indian Pediatr; 1996 Nov; 33(11):971. PubMed ID: 9141838
    [No Abstract]   [Full Text] [Related]  

  • 16. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
    Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
    Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal gammopathy in human leishmaniasis.
    Randi ML; Ruzzon E; Tezza F; Tezza F; Pacquola E; Fabris F
    Neth J Med; 2006 Feb; 64(2):50-1. PubMed ID: 16517989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-emergence of visceral leishmaniasis in Gujarat, India.
    Sharma U; Redhu NS; Mathur P; Singh S
    J Vector Borne Dis; 2007 Sep; 44(3):230-2. PubMed ID: 17896628
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.